Publications by authors named "Ignacio Garcia-Ribas"

Claim this Profile
S
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet.
Astrid Paulus, Marius Zemaitis, Saulius Cicenas, Zanete Zvirbule, Annika Sanfridson, Ignacio Garcia-Ribas

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors.
Roger B Cohen, Antonio Jimeno, Jennifer Hreno, Lova Sun, Marie Wallén-Öhman, Ignacio Garcia-Ribas

Invest New Drugs· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.
Eric Van Cutsem, Joelle Collignon, Rikke L Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Ignacio Garcia-Ribas

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Ignacio Garcia-Ribas

Cancer Res Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, Ahmad Awada, Bruno Coudert, Ignacio Garcia-Ribas

Breast Cancer Res Treat· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
Jaishri O Blakeley, Stuart A Grossman, Andrew S Chi, Tom Mikkelsen, Myrna R Rosenfeld

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Debra E Irwin, Brian Davis, Jill A Bell, Aaron Galaznik, Ignacio Garcia-Ribas

J Comp Eff Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Ignacio Garcia-Ribas

Melanoma Manag· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Antonio Llombart-Cussac, Begoña Bermejo, Cristian Villanueva, Suzette Delaloge, Serafín Morales, Ignacio Garcia-Ribas

Breast Cancer Res Treat· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Jaishri O Blakeley, Stuart A Grossman, Tom Mikkelsen, Myrna R Rosenfeld, David Peereboom

J Neurooncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Joyce O'Shaughnessy, Lee Schwartzberg, Michael A Danso, Kathy D Miller, Hope S Rugo, Ignacio Garcia-Ribas

J Clin Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Stijn L W Koolen, Petronella O Witteveen, Robert S Jansen, Marlies H G Langenberg, Roelien H Kronemeijer, Ignacio Garcia-Ribas

Clin Cancer Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Connexin-26 is a key factor mediating gemcitabine bystander effect.
Laura Garcia-Rodríguez, Sandra Pérez-Torras, Meritxell Carrió, Anna Cascante, Ignacio García-Ribas

Mol Cancer Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model.
Berta Laquente, Cristina Lacasa, Mireia M Ginestà, Oriol Casanovas, Agnès Figueras

Mol Cancer Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Joan Maurel Santasusana, José Luis García López, Juan José García, Ana Isabel León Carbonero, Javier Gallego Plazas

Clin Transl Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the value of confirming responses in clinical trials in oncology.
Jose Luis Perez-Gracia, Maria Muñoz, Grant Williams, Jun Wu, Eva Carrasco, Ignacio Garcia-Ribas

Eur J Cancer· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Juan Palou, Antonio Carcas, Jose Segarra, Blanca Duque, Jose Salvador, Ignacio Garcia-Ribas

J Urol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research.
Jose L Perez-Gracia, Maria Gloria Ruiz-Ilundain, Ignacio Garcia-Ribas, Eva Maria Carrasco

Cancer· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis